Journal
JOURNAL OF INVERTEBRATE PATHOLOGY
Volume 107, Issue -, Pages S42-S48Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.jip.2011.05.004
Keywords
VLP; Upstream processing; Downstream processing; Scalability; Modeling; Bioengineering challenges
Categories
Funding
- European Commission [LSHB-2006-037541, LSHB-2006-018933]
- Portuguese Fundacao para a Ciencia e a Tecnologia [PTDC/EQU-EQU/71645/2006, SFRH/BD/21910/2005, SFRH/BD/31257/2006]
- Fundação para a Ciência e a Tecnologia [PTDC/EQU-EQU/71645/2006, SFRH/BD/31257/2006, SFRH/BD/21910/2005] Funding Source: FCT
Ask authors/readers for more resources
Virus-like particles (VLPs) hold tremendous potential as vaccine candidates. These innovative biopharmaceuticals present the remarkable advantages of closely mimicking the three-dimensional nature of an actual virus while lacking the virus genome packaged inside its capsid. As a result, an equally efficient but safer prophylaxis is anticipated as compared to inactivated or live attenuated viral vaccines. With the advent of successful cases of approved VLP-based vaccines, pharmaceutical companies are indeed redirecting their resources to the development of such products. This paper reviews the current choices and trends of large-scale production and purification of VLP-based vaccines generated through the baculovirus expression vector system using insect cells. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available